Founded in Munich in 2020, Adragos’ global manufacturing sites were acquired from other players including Haupt Pharma Livron, LAW Pharma, Sanofi and Fresenius Kabi. They offer a range of services including drug development, manufacturing, and supply chain management.
The acquisition of Baccinex, which specializes in clinical trial supplies and smaller-scale commercial production, is designed to boost Adragos’ sterile manufacturing capabilities and expand its network.
As part of the deal, whose financials were undisclosed, Baccinex’s CEO Ursula Bausch will remain in her role as CEO and as a shareholder in the company.
Hailing the milestone deal for Adragos, CEO Andreas Raabe stated that “Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply. This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing.”
Back in April this year, Raabe told Outsourcing Pharma that the company is on the lookout for strategic acquisitions with the mission to double or even triple its size in the coming years.
Adragos focuses its CDMO efforts on small molecule treatments, which are seeing a resurgence of interest even as biologics and cell and gene therapies generate big excitement in the biotech industry.
The global market for fill finish manufacturing is set to soar by 8.9% per year from $16.7 billion in 2024 to $25.7 billion by 2029. This growth is being propelled by an increasing prevalence of chronic diseases leading to growing demand for injectable medications, as well as the industry shift toward precision medicine.
Adragos recently completed an ampoule filling line at its Livron facility in France, pumping in a €13 million ($14 million) investment to boost its production capacity to more than 160 million ampoules per year. The firm is also seeking to expand its foothold in the Japanese market following its absorption of Sanofi’s plant in Kawagoe City.
The rest of the CDMO space has also seen major exchanges of manufacturing capacity, with Novo Nordisk acquiring three fill-finish sites from Novo Holdings for $11 billion following the latter’s $16.5 billion acquisition of Catalent in February.
Additionally, the Taiwanese firm Bora Pharmaceuticals acquired Emergent BioSolutions’ sterile manufacturing facility in Maryland, US, in August this year, and the New Zealand animal health company Argenta acquired TriRx Pharmaceuticals’ Kansas-based manufacturing site and operations.